BriefingWire.com, 4/04/2012 - Immune Response BioPharma, Inc. Today Announces formulation changes for REMUNE HIV/AIDS Whole Killed Vaccine to once a month and once a week dosing. Changing the dosing of REMUNE is an important step to achieving increased results and defeating the HIV virus. The monthly dosing will remain at the old dosing of 100ug, the weekly dosing will be manufactured at 25ug per week, and the 3 month dosing will be increased to 400ug.
The original REMUNE 3 month dosing at 100ug will continue to be manufactured as this a well tested and safe dosing amount. For emergency approval of REMUNE this is a good dose to begin with as it will control and has shown slightly lower viral load.
Furthermore we will add to the REMUNE vaccine treatment, aspirin, lortadine and vitamin C to give patients a safe therapeutic treatment option over the HAART drugs. Adding aspirin to REMUNE for an anti-inflammatory effect, vitamin C to boost the immune system, and lortadine to help with allergic reactions from the virus.
“Changing the dosing and frequency of REMUNE is an important step to transforming the HIV/AIDS vaccine into a much more stronger and potent drug to defeat the virus. While the current dosing kept the virus in check and showed partial immunity it appears to not be strong enough in use with the HAART drugs as they are designed to destroy the virus it would appear they also interfere with the full benefits of REMUNE” IRBP CEO Mr. Buswell
“Monthly and weekly dosing to keep hammering the virus should be a big boost for REMUNE and its potential to defeat the virus. Also adding aspirin, lortadine and vitamin C to the REMUNE therapeutic treatment will help patients boost their immune systems. REMUNE has a role in treating HIV/AIDS i have many ideas to help patients with this terrible disease, perhaps experts in this field could learn a valuable lesson in the potential for combination treatments that are not toxic, you don’t toss away the most tested HIV/AIDS vaccine REMUNE and proven way to defeat a virus because of a few naive researchers and conflicts of interest, you figure out what you can do better and how to improve the vaccine results” IRBP CEO Mr. Buswell.
“Moving forward we are working on a corporate partnership for NeuroVax at the moment, and once that is completed we will work on REMUNE and our sepsis drug Sepsicillin. While a slow go of funding, our potential big pharma deal with NeuroVax will be a boom for our small biopharma and will lead to bigger and better things. Our team is focused on NeuroVax and developing a world class MS drug, safe once a month disease modifying MS vaccine that will revolutionize treatment for multiple sclerosis patients” IRBP CEO Mr. Buswell
Immune Response BioPharma, Inc. maybe found on the Worldwide Web at www.immuneresponsebiopharma.com
